RE: A matter of urgency14 Jul 2021 15:17
There is another reason to add to that list, GF.
Maybe we are not going into Agile? Maybe we will on licence 1801 to big pharma and they will take 1801 into trials. This is my prediction. The way we have kicked 1801 immune into next year suggests that 1801 will be trialled in Covid and that data, good or bad can be used to design the trails for 1801 immune.
There has been a lot of ramping here in the last few weeks and all in all, it has been fun but the reality is, as of yet we have no idea if 1801 is any good in humans. If it is good, it has to be proved safe, if it is safe, it has to be proved to work better than Dexamathazone and it has to be cheap or most governments will fall back on Dexamethasone. The big positive in all this is the data we can collect for 1801 Immune which was always a biggie anyway.
One criticism I have here is if Covid isn't a goer then we've waisted another year of development. I'm happy to trust the board here but I would also like some snippets of information. If nothing by the end of the month, I'll be seriously looking at my holding and protecting profits.